SCHEMBL12876310

SCHEMBL12876310

CCOC(=O)c1cnn(-c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
HPGD P15428 6/20 0.44
KDM4E B2RXH2 5/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
POLB P06746 2/20 0.44
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 4/20 0.44
GAA P10253 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 3/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 1/20 0.41
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
TSHR P16473 2/20 0.39
CRHBP P24387 1/20 0.39
MC4R P32245 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1197608 0.88 KDM4E (0.60) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12876327 0.88 MEN1 (0.48) KDM4EL3MBTL1KMT2AALDH1A1MEN1
SCHEMBL12875652 0.85 MAPT (0.52) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875515 0.82 KDM4E (0.59) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875625 0.81 MAPT (0.53) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875641 0.81 MAPT (0.55) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875649 0.79 MAPT (0.53) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875632 0.79 MAPT (0.47) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875628 0.78 MAPT (0.46) MAPTHPGDKDM4EL3MBTL1POLB
SCHEMBL12875645 0.77 MAPT (0.54) MAPTHPGDKDM4EL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MAPT 4667/4885HPGD 74/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.